Dactinomycin

Details

• Internal ID: 46b19226-31fa-4acb-8fe0-0489c3f5155a
• Taxonomy: Organic acids and derivatives > Peptidomimetics > Depsipeptides > Cyclic depsipeptides
• IUPAC Name: 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
• InChI: InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
• InChI Key: RJURFGZVJUQBHK-IIXSONLDSA-N
• Popularity: 23,783 references in papers

Physical and Chemical Properties

• Molecular Formula: C₆₂H₈₆N₁₂O₁₆
• Molecular Weight: 1255.40 g/mol
• Exact Mass: 1254.62847470 g/mol
• Topological Polar Surface Area (TPSA): 356.00 Ų
• XlogP: 3.80
• Atomic LogP (AlogP): 0.73
• H-Bond Acceptor: 18
• H-Bond Donor: 5
• Rotatable Bonds: 8

Synonyms

• actinomycin D
• Actinomycin C1
• Actinomycin IV
• Meractinomycin
• 50-76-0
• Cosmegen
• Actinomycin I1
• Dactinomycinum
• Cosmegen Lyovac
• Lyovac-Cosmegen
• Chounghwamycin B
• ActD
• Actinomycin X1
• Dilactone actinomycin D acid
• Oncostatin K
• Dactinomicina
• Dactinomycine
• ACTINOMYCIN-D
• Actinomycin I
• ACT D
• Actinomycin X 1
• Actinomycin A IV
• NCI-C04682
• Lyovac cosmegen
• Dactinomycin D
• GNF-Pf-2290
• Actinomycin I(sub 1)
• Actinomycin 7
• Actinomycin 11 cosmegen
• DTXSID9020031
• CCRIS 9
• Dactinomycine [INN-French]
• Dactinomycinum [INN-Latin]
• UNII-1CC1JFE158
• ACT [antibiotic]
• Dactinomicina [INN-Spanish]
• Actinomycin Aiv
• 1CC1JFE158
• CHEBI:27666
• HSDB 3220
• Acto-D
• NSC 3053
• NSC-3053
• EINECS 200-063-6
• Actinomycin C(sub1)
• DTXCID5031
• AI3-26374
• Dilactone actinomycindioic D acid
• MLS001424196
• ACT (antibiotic)
• Dactinomycin [USAN:USP:INN:BAN]
• HBF 386
• NCGC00161622-02
• Actinomycindioic D acid, dilactone
• SMR000469227
• Antibiotic from Streptomyces parvullus
• Actinomycin-(threo-val-pro-sar-meval)
• Dactinomycine (INN-French)
• Dactinomycinum (INN-Latin)
• Dactinomicina (INN-Spanish)
• Actinomycin D (Dactinomycin)
• ACTINOMYCIN D (IARC)
• ACTINOMYCIN D [IARC]
• DACTINOMYCIN (MART.)
• DACTINOMYCIN [MART.]
• X 97
• 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
• 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
• 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-
• DACTINOMYCIN (USP-RS)
• DACTINOMYCIN [USP-RS]
• NSC3053
• Dactinomycin (USAN:USP:INN:BAN)
• DACTINOMYCIN (USP MONOGRAPH)
• DACTINOMYCIN [USP MONOGRAPH]
• CAS-50-76-0
• 3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO-
• MFCD00005033
• AD (VAN)
• GNF-PF-1977
• actinomycin cl
• dactinomyein d
• actinomycin x i
• Glycopeptide, 4a
• 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-((18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetraazacyclohexadecin-9c-yl)-3H-phenoxazine-1,9-dicarboxamide
• 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-[(18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3H-phenoxazine-1,9-dicarboxamide
• 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide
• (-)-actinomycin d
• DACTINOMYCIN [MI]
• DACTINOMYCIN [INN]
• UPCMLD-DP055
• DACTINOMYCIN [HSDB]
• DACTINOMYCIN [USAN]
• SCHEMBL3844
• ACTINOMYCIN D [JAN]
• CHEMBL1554
• DACTINOMYCIN [VANDF]
• DACTINOMYCIN [WHO-DD]
• DACTINOMYCIN [WHO-IP]
• cid_457193
• NCI-CO4682
• ACTINOMYCIN D [WHO-IP]
• UPCMLD-DP055:001
• UPCMLD-DP055:002
• BDBM43866
• L01DA01
• RJURFGZVJUQBHK-IIXSONLDSA-N
• actinomyein-theo-val-pro-sar-meval
• DACTINOMYCIN [ORANGE BOOK]
• HMS2052O17
• Tox21_111997
• Tox21_202482
• Actinomycin-(thr-val-pro-sar-meval)
• BDBM50089528
• s8964
• DACTINOMYCINUM [WHO-IP LATIN]
• AKOS030228553
• Tox21_111997_1
• CCG-101134
• DB00970
• NC00384
• NCGC00090796-01
• NCGC00161622-01
• NCGC00260031-01
• NCGC00271789-02
• BP-25384
• Specific stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(N-methyl-L-valine) dilactone
• Stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis(carbonylimino(2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl)imino(2-(1-methylethyl)-1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino) (1-oxo-2,1-ethanediyl)))bis(N-methyl-L-valine)di-xi-lactone
• AB00514445-05
• EN300-7480748
• Q186127
• SR-01000763161
• SR-01000763161-4
• Actinomycin D, from Streptomyces sp., >=95% (HPLC)
• Actinomycin D, from Streptomyces sp., ~98% (HPLC)
• BRD-K70578146-001-01-8
• BRD-K70578146-001-04-2
• Dactinomycin, United States Pharmacopeia (USP) Reference Standard
• Actinomycin D, for fluorescence, >=90% (HPLC), from Streptomyces sp.
• Actinomycin D, from Streptomyces sp., suitable for cell culture, >=95%
• 1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
• 2-amino-4,6-dimethyl-3-oxo-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
• 2-amino-N,N''''''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
• 2-amino-N,N''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
• 2-amino-N,N''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
• 2-amino-N1,N9-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide
• 2-azanyl-4,6-dimethyl-3-oxidanylidene-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentakis(oxidanylidene)-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
• 2-bis(Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl))-1,9 dimethyl-4,6 3H-phenoxazinone-3
• 3H-phenoxazine-1,9-dicarboxamide, 2-Amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11, 14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6 -dimethyl-3-oxo-
• N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINE) DILACTONE
• N1,N9-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

2D Structure

ADMET Properties (via admetSAR 2)

Target	Value	Probability (raw)	Probability (%)
Human Intestinal Absorption	+	0.6825	68.25%
Caco-2	-	0.8566	85.66%
Blood Brain Barrier	-	0.9500	95.00%
Human oral bioavailability	-	0.6286	62.86%
Subcellular localzation	Nucleus	0.3958	39.58%
OATP2B1 inhibitior	-	0.8579	85.79%
OATP1B1 inhibitior	+	0.9413	94.13%
OATP1B3 inhibitior	+	0.9479	94.79%
MATE1 inhibitior	-	0.8023	80.23%
OCT2 inhibitior	-	0.8500	85.00%
BSEP inhibitior	+	0.9698	96.98%
P-glycoprotein inhibitior	+	0.7454	74.54%
P-glycoprotein substrate	+	0.8649	86.49%
CYP3A4 substrate	+	0.7064	70.64%
CYP2C9 substrate	+	0.7925	79.25%
CYP2D6 substrate	-	0.8524	85.24%
CYP3A4 inhibition	-	0.8614	86.14%
CYP2C9 inhibition	-	0.9071	90.71%
CYP2C19 inhibition	-	0.9025	90.25%
CYP2D6 inhibition	-	0.9230	92.30%
CYP1A2 inhibition	-	0.9045	90.45%
CYP2C8 inhibition	+	0.6524	65.24%
CYP inhibitory promiscuity	-	0.8681	86.81%
UGT catelyzed	-	0.0000	0.00%
Carcinogenicity (binary)	-	0.9300	93.00%
Carcinogenicity (trinary)	Non-required	0.6015	60.15%
Eye corrosion	-	0.9870	98.70%
Eye irritation	-	0.8969	89.69%
Skin irritation	-	0.7807	78.07%
Skin corrosion	-	0.9344	93.44%
Ames mutagenesis	-	0.8700	87.00%
Human Ether-a-go-go-Related Gene inhibition	+	0.7455	74.55%
Micronuclear	+	0.8400	84.00%
Hepatotoxicity	+	0.9092	90.92%
skin sensitisation	-	0.8785	87.85%
Respiratory toxicity	+	0.7889	78.89%
Reproductive toxicity	+	0.9778	97.78%
Mitochondrial toxicity	+	1.0000	100.00%
Nephrotoxicity	-	0.6418	64.18%
Acute Oral Toxicity (c)	I	0.8168	81.68%
Estrogen receptor binding	+	0.8906	89.06%
Androgen receptor binding	+	0.8696	86.96%
Thyroid receptor binding	+	0.6319	63.19%
Glucocorticoid receptor binding	+	0.6981	69.81%
Aromatase binding	+	0.8685	86.85%
PPAR gamma	+	0.8709	87.09%
Honey bee toxicity	-	0.7581	75.81%
Biodegradation	-	0.8250	82.50%
Crustacea aquatic toxicity	-	0.5800	58.00%
Fish aquatic toxicity	+	0.9078	90.78%

Targets

Proven Targets:

CHEMBL ID	UniProt ID	Name	Min activity	Assay type	Source
CHEMBL5514	P42858	Huntingtin	31.6 nM	Potency	via Super-PRED
CHEMBL4261	Q16665	Hypoxia-inducible factor 1 alpha	251.2 nM	Potency	via Super-PRED
CHEMBL1293232	Q16637	Survival motor neuron protein	316.2 nM; 354.8 nM	Potency; Potency	via Super-PRED; via Super-PRED

Predicted Targets (via Super-PRED):

CHEMBL ID	UniProt ID	Name	Probability	Model accuracy
CHEMBL2581	P07339	Cathepsin D	96.17%	98.95%
CHEMBL3038477	P67870	Casein kinase II alpha/beta	95.82%	99.23%
CHEMBL5409	Q8TDU6	G-protein coupled bile acid receptor 1	93.93%	93.65%
CHEMBL5845	P23415	Glycine receptor subunit alpha-1	93.62%	90.71%
CHEMBL1293277	O15118	Niemann-Pick C1 protein	92.81%	81.11%
CHEMBL3108638	O15164	Transcription intermediary factor 1-alpha	92.30%	95.56%
CHEMBL3837	P07711	Cathepsin L	89.17%	96.61%
CHEMBL5608	Q16288	NT-3 growth factor receptor	89.04%	95.89%
CHEMBL3251	P19838	Nuclear factor NF-kappa-B p105 subunit	88.84%	96.09%
CHEMBL2635	P51452	Dual specificity protein phosphatase 3	88.76%	94.00%
CHEMBL1907600	Q00535	Cyclin-dependent kinase 5/CDK5 activator 1	88.70%	93.03%
CHEMBL3359	P21462	Formyl peptide receptor 1	88.10%	93.56%
CHEMBL3137262	O60341	LSD1/CoREST complex	87.99%	97.09%
CHEMBL2069156	Q14145	Kelch-like ECH-associated protein 1	86.32%	82.38%
CHEMBL5103	Q969S8	Histone deacetylase 10	81.73%	90.08%
CHEMBL5966	P55899	IgG receptor FcRn large subunit p51	81.31%	90.93%
CHEMBL2378	P30307	Dual specificity phosphatase Cdc25C	80.73%	96.67%

Plants that contains it

There are no matching plants.

Cross-Links

• PubChem: 457193
• LOTUS: LTS0119305
• wikiData: Q186127